Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 1344546
Species: Homo sapiens
RGD Object: Gene
Symbol: TFPI
Name: tissue factor pathway inhibitor
Acc ID: CHEBI:31638
Term: fulvestrant
Definition: A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.
Chemical ID: MESH:C070081
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
TFPIdecreases secretionEXP 6480464CTDfulvestrant results in decreased secretion of TFPI proteinPMID:17029634
TFPIincreases expressionEXP 6480464CTDfulvestrant results in increased expression of TFPI mRNAPMID:26865669
TFPImultiple interactionsEXP 6480464CTD[fulvestrant co-treated with Raloxifene Hydrochloride] results in increased secretion of TFPI protein; fulvestrant inhibits the reaction [Raloxifene Hydrochloride results in decreased expression of and results in decreased secretion of TFPI protein]PMID:17029634
TFPImultiple interactionsISOTfpi (Rattus norvegicus)6480464CTDfulvestrant inhibits the reaction [Ethinyl Estradiol results in decreased activity of TFPI protein]; fulvestrant inhibits the reaction [norethindrone acetate results in decreased activity of TFPI protein]PMID:15857755
Go Back to source page   Continue to Ontology report